Were investors placing no value on the Symlin program in obesity?
I was not. The drug is interesting but if I recall correctly AMLN sold their interest for milestones and 20% royalty and it would be at least 5 years to market. Too far away with too much speculation with too little in terms of royalty income to mean much with AMLN's current marketcap.
EXEL is the XL-184 company and AMLN is the bydureon company for better or worse until they come up with something a little closer with more clarity to commercialization.
This said, yeah, it was surprising to see such a non-response as many AMLN bulls focus on this drug.
One point of clarification, unless I missed something (as I might have when I read the headline I figured it was pramlintide and metreleptin and not Symlin) but I don't believe Symlin is the drug in question, it is the combination trial of pralintide and metreleptin that was halted. These are the drugs in the Takeda deal.
Market Data 
Markets 
AI
